Search
New MSK research measures unscheduled healthcare interactions in multiple myeloma patients receiving T cell redirection therapies; investigates oral bacteria’s link to gut microbiota depletion with implications for cancer patients; and shows how a universal opt-out approach could help more cancer patients quit smoking.
In this Q&A, Memorial Sloan Kettering chemist Derek Tan discusses why natural products offer inspiration for the development of new drugs.
Memorial Sloan Kettering Cancer Center (MSK) announced that Cardinale Smith, MD, PhD, has joined the institution as the inaugural Chief Medical Officer (CMO).
Proton beam radiotherapy resulted in similar oncologic outcomes with less toxicity and improved quality of life than photon beam radiotherapy in patients with head and neck cancers, according to results of an MSK-led clinical trial presented today at the 2025 American Society for Radiation Oncology Annual Meeting.
A new study from Memorial Sloan Kettering’s (MSK) Marcel van den Brink— in collaboration with Jarrod Dudakov, PhD, at the Fred Hutchinson Cancer Center — has identified a molecule that promotes thymus regeneration. The results could pave the way toward treatments that could one day help rejuvenate an aging or damaged thymus. For more information or to speak with an expert, contact Rebecca Williams at [email protected].
Charles L. Sawyers, Chair of the Human Oncology and Pathogenesis Program, has been awarded the 2009 Dorothy P. Landon Prize for Translational Cancer Research from the American Association for Cancer Research.
Memorial Sloan Kettering Cancer Center (MSK) today announced the following awards and appointments:
Learn why medical oncologist Ghassan Abou-Alfa counsels his patients with liver cancer to stop drinking.
This photo essay showcases the critical role trainees play within MSK's research enterprise.
People with bladder cancer may soon have a new treatment option following surgery.